Tags : INO-4800

Inovio Reports FDA’s Partial Clinical Hold on P-II/III Trial of

Shots: The US FDA has put a partial clinical hold on P-II/III study of Inovio’s INO-4800, including its CELLECTRA 2000 delivery device to be used in the trial because it has additional questions about the trial Inovio is actively working to address the FDA’s questions and plans to respond in Oct’2020 after which the FDA […]Read More

Inovio to Initiate P-I/II Study of INO-4800 Against COVID-19 in

Shots: Inovio and IVI collaborate with Seoul National University Hospital to begin P-I/II clinical study of INO-4800 in South Korea The P-II study will assess the safety, tolerability, and immunogenicity of the INO-4800 vaccine in 40 adults aged 19-50 yrs. and will expand to enroll an additional 120 people aged 19-64 yrs. the companies expect […]Read More

Inovio Collaborates with Beijing Advaccine to Advance the Development of

Shots: Inovio is currently evaluating INO-4800 vaccine in P-I study assessing its safety and immunogenicity in the US and is supported by a grant of ~$9M from the Coalition for Epidemic Preparedness Innovations (CEPI) The focus of the collaboration is to deploy Advaccine’s expertise to initiate P-I study in China in parallel with its clinical […]Read More